Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.

Abstract

Sphingosine-1-phosphate receptor 1 (S1P1) plays an important role in autoimmune disease. Here, we evaluated whether ponesimod, an S1P1 modulator, affects inflammation in experimental autoimmune encephalomyelitis (EAE) and investigated Th1/Th2/Th17/Treg cell subsets. Ponesimod treatment ameliorated EAE and alleviated inflammatory infiltration. Compared with untreated EAE, ponesimod-treated mice had lower Th1 and Th17 cell numbers and higher Treg cell numbers; their IFN-γ, T-bet, IL-17, and RORγt levels as well as their pmTOR/mTOR ratio were diminished, while their TGF-β and Foxp3 levels were enhanced. These results suggest that ponesimod modulates the Th1/Th17/Treg balance and regulates the mTOR pathway.

• Authors: Huiqing Hou, Yafei Sun, Jun Miao, Mengying Gao, Li Guo, Xiujuan Song
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 356 Pg. 577583 (07 15 2021) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 33940233 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Inflammation Mediators
• Sphingosine 1 Phosphate Receptor Modulators
• Thiazoles
• ponesimod

Topics

• Animals
• Encephalomyelitis, Autoimmune, Experimental (drug therapy, immunology)
• Female
• Inflammation Mediators (antagonists & inhibitors, immunology)
• Mice
• Mice, Inbred C57BL
• Sphingosine 1 Phosphate Receptor Modulators (pharmacology, therapeutic use)
• T-Lymphocytes, Regulatory (drug effects, immunology)
• Th1 Cells (drug effects, immunology)
• Th17 Cells (drug effects, immunology)
• Thiazoles (pharmacology, therapeutic use)